Altria Group reported robust Q4 earnings, driven by NJOY's alternative products growth. Click here to see why MO stock is a ...

The healthcare industry is poised for growth driven by aging populations, technological advancements, and increased ...

Stratasys' stock surged over 20% after the company released preliminary fourth quarter results, even though results were ...

Medical device company Boston Scientific (NYSE:BSX) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 22.4% year on year to $4.56 billion. Guidance for next ...

Foresight's Growth VCTs invested an initial £4.5m in HSL in 2015, which supported the appointment of CEO Dominic Walsh.

A Belfast-based medical products distributor has been sold to a Scandinavian trade buyer in a deal which provides an exit for private equity and infrastructure investment manager Foresight Group.

AbbVie, Vertex Pharmaceuticals, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to ...

MO stock, with 41% returns since the beginning of 2024, has outperformed the S&P 500 index, up 27%. This can be attributed to the company’s decision to reduce its stake in Anheuser-Busch InBev last ...

Needham analyst David Saxon reiterated a Buy rating on DENTSPLY SIRONA (XRAY – Research Report) today and set a price target of $25.00.Invest ...

Several ASX-listed companies are undertaking phase III clinical trials, the critical final stage before potential regulatory ...

The Peptide Synthesis market valued at US$ 0.78 Billion in 2023, is forecasted to grow at a robust CAGR of 11.7%, reaching US$ 0.81 Billion in ...

Altria's Q4 earnings matched expectations, with a $1 billion share buyback authorized and strong sales growth, while ...